Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials
Background Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [ 99m Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2013-08, Vol.20 (8), p.2590-2599 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2599 |
|---|---|
| container_issue | 8 |
| container_start_page | 2590 |
| container_title | Annals of surgical oncology |
| container_volume | 20 |
| creator | Wallace, Anne M. Han, Linda K. Povoski, Stephen P. Deck, Kenneth Schneebaum, Schlomo Hall, Nathan C. Hoh, Carl K. Limmer, Karl K. Krontiras, Helen Frazier, Thomas G. Cox, Charles Avisar, Eli Faries, Mark King, Dennis W. Christman, Lori Vera, David R. |
| description | Background
Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [
99m
Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.
Methods
A total of 13 centers contributed 148 patients with breast cancer. Each patient received [
99m
Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [
99m
Tc]tilmanocept.
Results
A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [
99m
Tc]tilmanocept for a concordance rate of 99.04 % (
p
|
| doi_str_mv | 10.1245/s10434-013-2887-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3705144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3014626181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-8d548c587281e075d2c8d594092108526665d9ea98f028d7f8fe5679064894883</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxi1ERUvhAbggS5xT_D9jDkiwaqHSAhWEE0KWSZxdV4kd7GRRH4D3xqstVTlwmtHMN7_5pA-hZ5ScUSbky0yJ4KIilFcMoK7gATqhskyEAvqw9ERBpZmSx-hxzteE0JoT-QgdMy6JoIKeoN-rOE422dnvHD7f2WEpbQw49vib1mPTfm_8MNoQWzfNuI8Jf3Fh9sENeH0zTlv8MXYOf7DT5MMG-4DfJmfzjFc2tC7hq0Ir-vwKf3Z5Gea8Bze_Ir7a2uwwx03ydshP0FFfint6W0_R14vzZvW-Wn96d7l6s65aSfhcQScFtBJqBtSRWnasLSMtiGaUgGRKKdlpZzX0hEFX99A7qWpNlAAtAPgpen3gTsuP0XVtsZbsYKbkR5tuTLTe_LsJfms2cWd4TSQVogBe3AJS_Lm4PJvruKRQPBvKNSjCa-BFRQ-qNsWck-vvPlBi9smZQ3KmJGf2yZm9tef3rd1d_I2qCNhBkMsqbFy69_q_1D_XhqO6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1398603783</pqid></control><display><type>article</type><title>Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Wallace, Anne M. ; Han, Linda K. ; Povoski, Stephen P. ; Deck, Kenneth ; Schneebaum, Schlomo ; Hall, Nathan C. ; Hoh, Carl K. ; Limmer, Karl K. ; Krontiras, Helen ; Frazier, Thomas G. ; Cox, Charles ; Avisar, Eli ; Faries, Mark ; King, Dennis W. ; Christman, Lori ; Vera, David R.</creator><creatorcontrib>Wallace, Anne M. ; Han, Linda K. ; Povoski, Stephen P. ; Deck, Kenneth ; Schneebaum, Schlomo ; Hall, Nathan C. ; Hoh, Carl K. ; Limmer, Karl K. ; Krontiras, Helen ; Frazier, Thomas G. ; Cox, Charles ; Avisar, Eli ; Faries, Mark ; King, Dennis W. ; Christman, Lori ; Vera, David R.</creatorcontrib><description>Background
Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [
99m
Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.
Methods
A total of 13 centers contributed 148 patients with breast cancer. Each patient received [
99m
Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [
99m
Tc]tilmanocept.
Results
A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [
99m
Tc]tilmanocept for a concordance rate of 99.04 % (
p
< 0.0001). [
99m
Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [
99m
Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131,
p
< 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [
99m
Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (
p
= 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [
99m
Tc]tilmanocept.
Conclusion
[
99m
Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [
99m
Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-013-2887-8</identifier><identifier>PMID: 23504141</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Axilla ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - pathology ; Breast Oncology ; Coloring Agents ; Dextrans - adverse effects ; Female ; Humans ; Lymph Nodes - diagnostic imaging ; Lymph Nodes - pathology ; Lymph Nodes - surgery ; Lymphatic Metastasis ; Mannans - adverse effects ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Radionuclide Imaging ; Radiopharmaceuticals - adverse effects ; Sentinel Lymph Node Biopsy - methods ; Surgery ; Surgical Oncology ; Technetium Tc 99m Pentetate - adverse effects ; Technetium Tc 99m Pentetate - analogs & derivatives</subject><ispartof>Annals of surgical oncology, 2013-08, Vol.20 (8), p.2590-2599</ispartof><rights>The Author(s) 2013</rights><rights>Society of Surgical Oncology 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-8d548c587281e075d2c8d594092108526665d9ea98f028d7f8fe5679064894883</citedby><cites>FETCH-LOGICAL-c503t-8d548c587281e075d2c8d594092108526665d9ea98f028d7f8fe5679064894883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-013-2887-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-013-2887-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23504141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wallace, Anne M.</creatorcontrib><creatorcontrib>Han, Linda K.</creatorcontrib><creatorcontrib>Povoski, Stephen P.</creatorcontrib><creatorcontrib>Deck, Kenneth</creatorcontrib><creatorcontrib>Schneebaum, Schlomo</creatorcontrib><creatorcontrib>Hall, Nathan C.</creatorcontrib><creatorcontrib>Hoh, Carl K.</creatorcontrib><creatorcontrib>Limmer, Karl K.</creatorcontrib><creatorcontrib>Krontiras, Helen</creatorcontrib><creatorcontrib>Frazier, Thomas G.</creatorcontrib><creatorcontrib>Cox, Charles</creatorcontrib><creatorcontrib>Avisar, Eli</creatorcontrib><creatorcontrib>Faries, Mark</creatorcontrib><creatorcontrib>King, Dennis W.</creatorcontrib><creatorcontrib>Christman, Lori</creatorcontrib><creatorcontrib>Vera, David R.</creatorcontrib><title>Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [
99m
Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.
Methods
A total of 13 centers contributed 148 patients with breast cancer. Each patient received [
99m
Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [
99m
Tc]tilmanocept.
Results
A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [
99m
Tc]tilmanocept for a concordance rate of 99.04 % (
p
< 0.0001). [
99m
Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [
99m
Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131,
p
< 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [
99m
Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (
p
= 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [
99m
Tc]tilmanocept.
Conclusion
[
99m
Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [
99m
Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Axilla</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Oncology</subject><subject>Coloring Agents</subject><subject>Dextrans - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Lymph Nodes - diagnostic imaging</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - surgery</subject><subject>Lymphatic Metastasis</subject><subject>Mannans - adverse effects</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Radionuclide Imaging</subject><subject>Radiopharmaceuticals - adverse effects</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Technetium Tc 99m Pentetate - adverse effects</subject><subject>Technetium Tc 99m Pentetate - analogs & derivatives</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc9u1DAQxi1ERUvhAbggS5xT_D9jDkiwaqHSAhWEE0KWSZxdV4kd7GRRH4D3xqstVTlwmtHMN7_5pA-hZ5ScUSbky0yJ4KIilFcMoK7gATqhskyEAvqw9ERBpZmSx-hxzteE0JoT-QgdMy6JoIKeoN-rOE422dnvHD7f2WEpbQw49vib1mPTfm_8MNoQWzfNuI8Jf3Fh9sENeH0zTlv8MXYOf7DT5MMG-4DfJmfzjFc2tC7hq0Ir-vwKf3Z5Gea8Bze_Ir7a2uwwx03ydshP0FFfint6W0_R14vzZvW-Wn96d7l6s65aSfhcQScFtBJqBtSRWnasLSMtiGaUgGRKKdlpZzX0hEFX99A7qWpNlAAtAPgpen3gTsuP0XVtsZbsYKbkR5tuTLTe_LsJfms2cWd4TSQVogBe3AJS_Lm4PJvruKRQPBvKNSjCa-BFRQ-qNsWck-vvPlBi9smZQ3KmJGf2yZm9tef3rd1d_I2qCNhBkMsqbFy69_q_1D_XhqO6</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Wallace, Anne M.</creator><creator>Han, Linda K.</creator><creator>Povoski, Stephen P.</creator><creator>Deck, Kenneth</creator><creator>Schneebaum, Schlomo</creator><creator>Hall, Nathan C.</creator><creator>Hoh, Carl K.</creator><creator>Limmer, Karl K.</creator><creator>Krontiras, Helen</creator><creator>Frazier, Thomas G.</creator><creator>Cox, Charles</creator><creator>Avisar, Eli</creator><creator>Faries, Mark</creator><creator>King, Dennis W.</creator><creator>Christman, Lori</creator><creator>Vera, David R.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20130801</creationdate><title>Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials</title><author>Wallace, Anne M. ; Han, Linda K. ; Povoski, Stephen P. ; Deck, Kenneth ; Schneebaum, Schlomo ; Hall, Nathan C. ; Hoh, Carl K. ; Limmer, Karl K. ; Krontiras, Helen ; Frazier, Thomas G. ; Cox, Charles ; Avisar, Eli ; Faries, Mark ; King, Dennis W. ; Christman, Lori ; Vera, David R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-8d548c587281e075d2c8d594092108526665d9ea98f028d7f8fe5679064894883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Axilla</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Oncology</topic><topic>Coloring Agents</topic><topic>Dextrans - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Lymph Nodes - diagnostic imaging</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - surgery</topic><topic>Lymphatic Metastasis</topic><topic>Mannans - adverse effects</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Radionuclide Imaging</topic><topic>Radiopharmaceuticals - adverse effects</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Technetium Tc 99m Pentetate - adverse effects</topic><topic>Technetium Tc 99m Pentetate - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wallace, Anne M.</creatorcontrib><creatorcontrib>Han, Linda K.</creatorcontrib><creatorcontrib>Povoski, Stephen P.</creatorcontrib><creatorcontrib>Deck, Kenneth</creatorcontrib><creatorcontrib>Schneebaum, Schlomo</creatorcontrib><creatorcontrib>Hall, Nathan C.</creatorcontrib><creatorcontrib>Hoh, Carl K.</creatorcontrib><creatorcontrib>Limmer, Karl K.</creatorcontrib><creatorcontrib>Krontiras, Helen</creatorcontrib><creatorcontrib>Frazier, Thomas G.</creatorcontrib><creatorcontrib>Cox, Charles</creatorcontrib><creatorcontrib>Avisar, Eli</creatorcontrib><creatorcontrib>Faries, Mark</creatorcontrib><creatorcontrib>King, Dennis W.</creatorcontrib><creatorcontrib>Christman, Lori</creatorcontrib><creatorcontrib>Vera, David R.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wallace, Anne M.</au><au>Han, Linda K.</au><au>Povoski, Stephen P.</au><au>Deck, Kenneth</au><au>Schneebaum, Schlomo</au><au>Hall, Nathan C.</au><au>Hoh, Carl K.</au><au>Limmer, Karl K.</au><au>Krontiras, Helen</au><au>Frazier, Thomas G.</au><au>Cox, Charles</au><au>Avisar, Eli</au><au>Faries, Mark</au><au>King, Dennis W.</au><au>Christman, Lori</au><au>Vera, David R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>20</volume><issue>8</issue><spage>2590</spage><epage>2599</epage><pages>2590-2599</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [
99m
Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.
Methods
A total of 13 centers contributed 148 patients with breast cancer. Each patient received [
99m
Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [
99m
Tc]tilmanocept.
Results
A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [
99m
Tc]tilmanocept for a concordance rate of 99.04 % (
p
< 0.0001). [
99m
Tc]tilmanocept detected a total of 320 nodes, of which 207 (64.7 %) were detected by VBD. [
99m
Tc]Tilmanocept detected at least 1 SLN in more patients (146) than did VBD (131,
p
< 0.0001). In 129 of 131 patients with ≥1 blue node, all blue nodes were radioactive. Of 33 pathology-positive nodes (18.2 % patient pathology rate), [
99m
Tc]tilmanocept detected 31 of 33, whereas VBD detected only 25 of 33 (
p
= 0.0312). No pathology-positive SLNs were detected exclusively by VBD. No serious adverse events were attributed to [
99m
Tc]tilmanocept.
Conclusion
[
99m
Tc]Tilmanocept demonstrated success in detecting a SLN while meeting the primary endpoint. Interestingly, [
99m
Tc]tilmanocept was additionally noted to identify more SLNs in more patients. This localization represented a higher number of metastatic breast cancer lymph nodes than that of VBD.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23504141</pmid><doi>10.1245/s10434-013-2887-8</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2013-08, Vol.20 (8), p.2590-2599 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3705144 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Axilla Breast Neoplasms - diagnostic imaging Breast Neoplasms - pathology Breast Oncology Coloring Agents Dextrans - adverse effects Female Humans Lymph Nodes - diagnostic imaging Lymph Nodes - pathology Lymph Nodes - surgery Lymphatic Metastasis Mannans - adverse effects Medicine Medicine & Public Health Middle Aged Oncology Radionuclide Imaging Radiopharmaceuticals - adverse effects Sentinel Lymph Node Biopsy - methods Surgery Surgical Oncology Technetium Tc 99m Pentetate - adverse effects Technetium Tc 99m Pentetate - analogs & derivatives |
| title | Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Evaluation%20of%20%5B99mTc%5DTilmanocept%20for%20Sentinel%20Lymph%20Node%20Mapping%20in%20Breast%20Cancer%20Patients:%20Results%20of%20Two%20Phase%203%20Trials&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Wallace,%20Anne%20M.&rft.date=2013-08-01&rft.volume=20&rft.issue=8&rft.spage=2590&rft.epage=2599&rft.pages=2590-2599&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-013-2887-8&rft_dat=%3Cproquest_pubme%3E3014626181%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1398603783&rft_id=info:pmid/23504141&rfr_iscdi=true |